

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/754,998	01/04/2001	Ernst H. Rinderknecht	P0941C1D1C1	4682
9157	7590 05/09/2002			
GENENTECH, INC.		EXAMINER		
1 DNA WAY			HELMS, LARRY RONALD	
SOUTH SAN	FRANCISCO, CA 94080			_
			ART UNIT	PAPER NUMBER
			1642	
			DATE MAILED: 05/09/2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/754,998	RINDERKNECHT ET AL	
Office Action Summary	Examiner	Art Unit	
	Larry R. Helms	1642	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	86(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
1) Responsive to communication(s) filed on	·		
·— · · · · · · · · · · · · · · · · · ·	s action is non-final.		
3) Since this application is in condition for allowa closed in accordance with the practice under the	•		
Disposition of Claims			
4) Claim(s) 19-29 is/are pending in the applicatio	n.		
4a) Of the above claim(s) is/are withdraw	vn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) 19-29 are subject to restriction and/or	election requirement.		
Application Papers			
9)☐ The specification is objected to by the Examiner			
10) ☐ The drawing(s) filed on is/are: a) ☐ accep	ted or b)⊡ objected to by the Exar	miner.	
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).	
11)☐ The proposed drawing correction filed on	is: a) approved b) disappro	ved by the Examiner.	
If approved, corrected drawings are required in rep	ly to this Office action.		
12) The oath or declaration is objected to by the Exa	aminer.		
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a))-(d) or (f).	
a) All b) Some * c) None of:			
 Certified copies of the priority documents 	have been received.		
2. Certified copies of the priority documents	have been received in Application	on No	
 3. Copies of the certified copies of the prior application from the International Bur * See the attached detailed Office action for a list of 	eau (PCT Rule 17.2(a)).	•	
	•		
14) Acknowledgment is made of a claim for domestic			
 a) ☐ The translation of the foreign language production 15)☒ Acknowledgment is made of a claim for domestic 	• •		
Attachment(s)		with the transfer of the trans	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)	

Application/Control Number: 09/754,998

Art Unit: 1642

Election/Restrictions

1. This application contains claims directed to the following patentably distinct species of the claimed invention:

Species A: an antibody that binds p185HER2

Species B: an antibody that binds CD18

The species are distinct because each antibody binds an antigen that is patentably distinct and distinct in both structure and function and an antibody that binds CD18 would not necessarily bind p185HER2...

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 19-27 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 09/754,998 Page 4

Art Unit: 1642

Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242.

Respectfully, Larry R. Helms Ph.D. 703-306-5879



Creation date: 10-27-2003

Indexing Officer: RCUNANAN - ROLANDO CUNANAN

Team: OIPEBackFileIndexing

Dossier: 09754998

Legal Date: 06-06-2002

No.	Doccode	Number of pages
1	A	1

Total number of pages: 1

Remarks:

Order of re-scan issued on